Genetic Risk Factors for Pulmonary Arterial Hypertension

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on Genetics & Health. Browse all Genetics & Health education

Pulmonary arterial hypertension (PAH) is a rare, serious condition in which the small arteries of the lungs narrow and stiffen, forcing the right side of the heart to work harder to push blood through. Some people develop PAH with no identifiable cause; in others, a clear genetic driver runs through the family. Knowing the genetic risk factors matters because PAH is easier to manage when it is recognized early — and because relatives of affected people may benefit from screening.

What PAH is

In PAH, the walls of the pulmonary arteries thicken and remodel, raising the pressure blood must overcome to reach the lungs. Over time this strains the right ventricle. Early symptoms — breathlessness on exertion, fatigue, chest discomfort, lightheadedness, and swelling in the legs — are easy to attribute to being out of shape, which is one reason PAH is often diagnosed late. Prompt evaluation by a healthcare provider when these symptoms appear is central to earlier detection.

BMPR2: the major gene

The single most important genetic risk factor is BMPR2, which encodes the bone morphogenetic protein receptor type 2. Mutations in BMPR2 are found in roughly 70 to 80 percent of families with heritable PAH and in about 20 percent of people with what initially appears to be idiopathic PAH. BMPR2 normally helps keep the growth of the cells lining pulmonary arteries in check; when it fails, those cells can proliferate and narrow the vessel. Inheritance is autosomal dominant — a child of a carrier has a 50 percent chance of inheriting the mutation.

Other genes involved

BMPR2 sits within a larger network. Mutations in ACVRL1 and ENG — genes also tied to hereditary hemorrhagic telangiectasia — can cause PAH, as can variants in KCNK3, TBX4, and SOX17. A distinct pattern involves EIF2AK4: biallelic (recessive) mutations are associated with pulmonary veno-occlusive disease, a rare PAH-related condition. Together these genes point to shared biology in how pulmonary vessels grow and remodel.

Incomplete penetrance and family screening

A crucial feature of PAH genetics is incomplete penetrance. Only about 20 percent of people who inherit a BMPR2 mutation ever develop PAH, and women are affected more often than men. This means a positive genetic result identifies elevated risk, not certainty — and a negative result in a family with a known mutation can be reassuring. Because of these dynamics, genetic counseling and clinical screening of at-risk relatives are handled by specialists who can interpret results in context.

Early detection and provider-directed management

PAH management is highly specialized and directed entirely by pulmonary hypertension experts; this article does not provide treatment or dosing guidance. The key public message is that early detection improves the outlook: people with symptoms such as unexplained breathlessness, and relatives of those with heritable PAH, should seek evaluation. Diagnosis relies on specialized testing, including right-heart catheterization, performed by a qualified care team.

What pathway-level genetic insight offers

Vascular and signaling genetics is where PAH research is advancing quickly. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across peptide-related biological pathways, offering pathway-level context about your biology rather than a diagnosis of PAH or any cardiovascular condition. It does not diagnose, treat, or predict pulmonary arterial hypertension. Concerns about PAH risk — especially with a family history — belong with a healthcare provider who can arrange appropriate genetic counseling and testing.

Frequently Asked Questions

Is pulmonary arterial hypertension hereditary?

Some cases are. Heritable PAH is most often caused by BMPR2 mutations, inherited in an autosomal dominant pattern, and other genes such as ACVRL1, ENG, and EIF2AK4 also contribute. Many cases, however, are idiopathic or linked to other conditions rather than a single inherited mutation.

If I inherit a BMPR2 mutation, will I develop PAH?

Not necessarily. BMPR2 shows incomplete penetrance: only about 20 percent of carriers develop PAH, and women are affected more often than men. A mutation signals elevated risk that warrants monitoring and genetic counseling, not a certainty that the disease will occur.

Should family members of a PAH patient be tested?

When a heritable mutation is identified, specialists may recommend genetic counseling and screening for at-risk relatives. This is decided case by case with a care team, because results guide monitoring rather than diagnosis. Any testing should occur with professional interpretation and support.

How is PAH detected early?

Early detection depends on taking symptoms such as unexplained breathlessness, fatigue, and fainting seriously and seeking prompt evaluation. Providers use echocardiography as a screen and confirm PAH with right-heart catheterization. Relatives of people with heritable PAH may be monitored proactively by specialists.

Interested in pathway-level context on your vascular and signaling genetics? Take the Precision Peptide Genetic Test to see what pathway-level genetic context can add to your conversation with a qualified provider.

Disclaimer: The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

This article is part of the PlexusDx Education Hub. Browse all Genetics & Health education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.